



Review Article

Review on Process Analytical Technology in Pharmaceutical Manufacturing

Akshaya A.¹, Sarumathi B.¹, Roja K.*², Saminathan C.³

¹Mayor Radhakrishnan College of Pharmacy, Chennai, Tamil Nadu, India.

²Assistant Professor, Department of pharmaceutical chemistry, Mayor Radhakrishnan College of Pharmacy, Chennai, Tamil Nadu, India

³Principal & Professor Department of Pharmaceutics, Mayor Radhakrishnan College of Pharmacy, Chennai, Tamil Nadu, India

Process Analytical Technology (PAT) has emerged as a transformative framework in pharmaceutical manufacturing, enabling the transition from conventional end-product testing to science-based, real-time process monitoring and control. Introduced by the United States Food and Drug Administration (USFDA), PAT integrates advanced analytical techniques, multivariate data analysis, chemometric tools, and process control strategies to ensure consistent product quality throughout the manufacturing process. This review provides a comprehensive overview of the principles, objectives, and key components of PAT, emphasizing its role in monitoring Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), and Critical Material Attributes (CMAs). The review discusses the working principles, methodologies, industrial significance, and pharmaceutical applications of major PAT tools, including Near-Infrared (NIR) spectroscopy, Raman spectroscopy, UV-Visible spectroscopy, High-Performance Liquid Chromatography (HPLC), particle size analyzers, and moisture analysis techniques. Furthermore, the applications of PAT in solid and liquid dosage form manufacturing, regulatory perspectives based on USFDA and International Council for Harmonisation (ICH) guidelines, implementation challenges, and future developments involving artificial intelligence, continuous manufacturing, and smart pharmaceutical factories are critically examined. By facilitating Quality by Design (QbD), Real-Time Release Testing (RTRT), and data-driven decision-making, PAT enhances process understanding, minimizes variability, reduces manufacturing costs, and improves regulatory compliance. Overall, PAT represents a cornerstone of modern pharmaceutical manufacturing and is expected to play a pivotal role in advancing efficient, robust, and sustainable production systems.

Keywords: Process Analytical Technology (PAT); Pharmaceutical Manufacturing; Critical Quality Attributes (CQAs); Critical Process Parameters (CPPs); Quality by Design (QbD); Real-Time Release Testing (RTRT); Near-Infrared.

INTRODUCTION

Pharmaceutical manufacturing is the large-scale production of medicines using active pharmaceutical ingredients (APIs) and excipients under Good Manufacturing Practices (GMP) to ensure product safety, quality and consistency. Maintaining consistent quality is essential because even minor manufacturing errors can affect patient health. Process Analytical Technology (PAT) enhances quality control through real-time monitoring and

control of manufacturing processes, enabling early detection of process deviations, reducing batch failures and ensuring that quality is built into the product rather than relying solely on final product testing.

Process Analytical Technology (PAT)

Process Analytical Technology (PAT) is a scientific framework introduced by the U.S. Food and Drug

Administration (FDA) to improve pharmaceutical manufacturing through real-time monitoring and control of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs). Unlike conventional quality testing, PAT focuses on process understanding and continuous monitoring rather than relying solely on end-product testing. By integrating advanced analytical tools, process control strategies, and data analysis techniques, PAT enables consistent product quality, reduces process variability, minimizes manufacturing failures, and supports Quality by Design (QbD), Real-Time Release Testing (RTRT), and continuous manufacturing.

Basic Concept Of PAT

Process Analytical Technology (PAT) is a scientific framework for designing, monitoring, and controlling pharmaceutical manufacturing through real-time measurement of critical quality and process attributes. Unlike traditional end-product testing, PAT focuses on continuous process monitoring to ensure consistent product quality.

Need for Pat in The Pharmaceutical Industry

PAT is essential for improving product quality, process efficiency, and manufacturing consistency. It enables real-time monitoring, reduces process variability and product failures, supports regulatory compliance, and promotes Quality by Design (QbD) and continuous manufacturing.

Important Terms in Process Analytical Technology (PAT)

Several key terms are essential for understanding the application of Process Analytical Technology (PAT) in pharmaceutical manufacturing:

- **Critical Quality Attributes (CQAs):** Physical, chemical, or biological properties that determine the quality of the final product (e.g., tablet hardness, dissolution, assay).
- **Critical Process Parameters (CPPs):** Manufacturing variables that directly influence product quality and must be carefully controlled (e.g., temperature, mixing speed, compression force).
- **Critical Material Attributes (CMAs):** Characteristics of raw materials that affect product quality, such as particle size and moisture content.
- **Design Space:** The approved operating range of process parameters that ensures consistent product quality.
- **Multivariate Data Analysis (MVDA):** Statistical methods used to analyse multiple process variables simultaneously for better process understanding and control.
- **Real-Time Release Testing (RTRT):** Product release based on real-time process monitoring instead of conventional end-product testing.
- **Continuous Manufacturing:** A manufacturing approach in which materials are continuously processed with real-time monitoring to ensure consistent quality.

Tools Used In PAT

Near-Infrared Spectroscopy (NIR)



Principle:

NIR measures the absorption of near-infrared light by chemical bonds (C–H, O–H, N–H), enabling rapid analysis of pharmaceutical materials. (Fig. 2)

Methodology:

An NIR probe is installed in processing equipment to collect real-time spectral data. Chemometric models analyze the spectra to monitor parameters such as moisture content, blend uniformity, and API concentration, allowing timely process control.

Applications:

- Blend uniformity monitoring
- Moisture content analysis
- Drying end-point detection
- Content uniformity testing

Industrial outlook

NIR is a widely used PAT tool because it is rapid, non-destructive, and supports real-time process monitoring, reducing the need for offline testing.

Raman Spectroscopy**Principle:**

Raman spectroscopy is based on the inelastic scattering of monochromatic light, producing a molecular fingerprint for compound identification. (Fig. 3)

Methodology:

A Raman probe collects real-time spectra from the manufacturing process. Chemometric models compare the spectra with reference data to identify raw materials, quantify API, and detect polymorphic changes.


Applications:

- Raw material identification
- API verification
- Polymorph detection
- Coating thickness monitoring

Industrial outlook

Raman spectroscopy is a highly specific PAT tool widely used for solid-state analysis, process monitoring, and counterfeit drug detection.

UV-Visible Spectroscopy

**Principle:**

UV-Visible spectroscopy measures the absorption of ultraviolet or visible light by molecules. The absorbance follows the Beer–Lambert law, which relates absorbance to concentration.

Methodology:

Fiber-optic probes monitor samples in real time by measuring absorbance at specific wavelengths. The data are converted into concentration profiles for process control and adjustment.

Applications:

- Drug concentration monitoring
- Dissolution testing
- Reaction monitoring

Industrial outlook

UV-Visible spectroscopy is a simple, rapid, and cost-effective PAT tool widely used for liquid formulations and real-time process monitoring.

High-Performance Liquid Chromatography (HPLC)**Principle:**

HPLC separates and quantifies components based on their interaction with the mobile and stationary phases.

Methodology:

In PAT, automated sampling systems collect samples from the production line, and HPLC analysis provides rapid feedback on assay, impurities, and degradation products.


Applications:

- Impurity profiling
- Assay determination
- Stability testing
- Quality verification

Industrial outlook

HPLC remains a reliable PAT tool due to its high accuracy and specificity, particularly for impurity and stability analysis.

Particle Size Analyzer (Laser Diffraction)



Principle:

Laser diffraction determines particle size distribution by measuring light scattering patterns from particles.

Methodology:

In PAT, in-line laser systems continuously monitor particle size parameters such as D10, D50, and D90 during milling and granulation, enabling immediate process adjustments.

Applications:

- Milling process monitoring
- Granulation control
- API particle size analysis

Industrial outlook:

Real-time particle size monitoring improves dissolution, bioavailability, and product consistency.

Moisture Analysis



Principle:

Moisture analysis determines water and volatile content in pharmaceutical materials. (Fig. 7)

Methodology:

PAT uses in-line NIR or microwave sensors to monitor moisture levels during drying and enables real-time process control.

Applications:

- Granule moisture monitoring
- Powder and raw material analysis

- Quality control testing

Industrial outlook:

Moisture monitoring improves product stability, tablet compression, and overall quality.

Advantages Of PAT**Improves Product Quality**

- Enables real-time monitoring of critical quality attributes (CQAs).
- Ensures product uniformity and reduces variability.

Reduces Batch Failure

- Detects process deviations early.
- Minimizes batch rejection, rework, and material wastage.

Saves Time and Cost

- Reduces reliance on end-product testing.
- Optimizes resource utilization and lowers production costs.

Faster Product Release

- Supports Real-Time Release Testing (RTRT).

Application of PAT In Manufacturing**Solid Dosage Forms**

PAT enables real-time monitoring of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) throughout tablet and capsule manufacturing.

Granulation

- Monitored: Moisture content, granule size, density.
- Significance: Ensures uniform granules and improves tablet quality.
- Tools: NIR spectroscopy, moisture sensors, particle size analyzer.

Mixing/Blending



- Monitored: Blend uniformity and mixing time.
- Tools: NIR and Raman spectroscopy.
- Significance: Prevents segregation and ensures dose uniformity.

Tablet Compression



- Monitored: Tablet weight, hardness, thickness, compression force.
- Tools: Weight and force sensors, hardness testers.
- Significance: Maintains tablet strength and consistent drug release.

Coating



- Monitored: Coating thickness, spray rate, temperature.
- Tools: NIR spectroscopy, temperature sensors, CCD cameras.

- Significance: Ensures uniform coating and desired dissolution profile.

PAT improves process control in liquid formulations by ensuring uniform mixing and consistent drug dissolution.

Liquid Dosage Forms

Mixing Uniformity



- Tools: NIR, Raman, and UV-Visible spectroscopy.
- Significance: Ensures dose uniformity and product stability.

Dissolution Monitoring



- Tools: UV-Visible spectroscopy, fiber-optic probes, HPLC.
- Significance: Confirms drug release and bioavailability.

supports Quality by Design (QbD), risk-based manufacturing, continuous improvement, and Real-Time Release Testing (RTRT) to ensure product quality and regulatory compliance.

Regulatory Aspects

FDA Guidance on PAT

The U.S. FDA defines Process Analytical Technology (PAT) as a framework for designing, analyzing, and controlling pharmaceutical manufacturing through real-time monitoring of critical quality attributes. The 2004 FDA guidance

ICH Guidelines

The International Council for Harmonisation (ICH) provides global guidelines for pharmaceutical quality, safety, and efficacy. The guidelines are classified into Quality (Q), Safety (S), Efficacy (E), and Multidisciplinary (M) categories, promoting harmonized regulatory submissions and consistent pharmaceutical development worldwide.

CHALLENGES IN IMPLEMENTING PAT

High Initial Cost

- Requires significant investment in analytical instruments, software, and infrastructure.

Skilled Personnel

- Demands expertise in analytical sciences, chemometrics, and process engineering, with ongoing training.

Complex Data Management

- Generates large volumes of real-time data requiring advanced analysis, integration, and secure storage.

Validation and Regulatory Compliance

- Validation of analytical models and RTRT, along with regulatory documentation, can be challenging.

System Integration

- Integration with existing manufacturing systems may face compatibility and organizational challenges.

FUTURE SCOPE OF PAT

Artificial Intelligence (AI)

- AI and Machine Learning (ML) will enhance real-time data analysis, predictive process control, automated decision-making, and product quality.

Continuous Manufacturing

- PAT will support continuous process monitoring, immediate process adjustments, and Real-Time Release Testing (RTRT), improving manufacturing efficiency.

Smart Factories

- Integration with the Internet of Things (IoT) will enable automated data exchange, predictive maintenance, and intelligent manufacturing with minimal human intervention.

RESULTS AND DISCUSSIONS

CONCLUSION

Process Analytical Technology (PAT) has become a cornerstone of modern pharmaceutical manufacturing. By enabling real-time monitoring, control, and optimization of critical process parameters, PAT ensures consistent product quality, process efficiency, and regulatory compliance. It supports continuous manufacturing, Real-Time Release Testing (RTRT), and aligns with Quality by Design (QbD) principles, facilitating a science-based, risk-managed approach to production. In the contemporary pharmaceutical industry, PAT not only reduces waste and production costs but also enhances process understanding, accelerates product development, and promotes innovation. Its integration with advanced analytics, automation, and smart manufacturing systems positions PAT as a key enabler for reliable, efficient, and high-quality pharmaceutical production.

ACKNOWLEDGEMENT

The authors express their sincere gratitude to the Principal of our institution for providing the facilities, encouragement, and academic environment necessary to complete this review work successfully. We would also like to extend our heartfelt thanks to all the faculty members and staff of the Department of Pharmacy for their valuable guidance, continuous support, and constructive suggestions throughout the preparation of this manuscript. Finally, we acknowledge all the researchers and authors whose published work has served as a valuable source of information and inspiration for this review.

JOURNAL REFERENCES

1. Arden NS, Fisher AC, Tyner K, et al. International Journal of Pharmaceutics. 2021; 602:120554.
2. Testa CJ, Hu C, Shvedova K, et al. Organic Process Research & Development. 2020;24(12):2874–2889.

3. Fan Y, Wang X, Funk T, et al. *Environmental Science & Technology*. 2022;56(19):13546–13564.
4. Munson J, Freeman Stanfield C, Gujral B. *Current Pharmaceutical Analysis*. 2006;2(4):405–414.
5. Hackett JL, Gutman SI. *Journal of Proteome Research*. 2005;4(4):1110–1113.
6. Rathore AS, Bhambure R, Ghare V. *Analytical and Bioanalytical Chemistry*. 2010;398(1):137–154.
7. Chew W, Sharratt P. *Analytical Methods*. 2010;2(10):1412–1438.
8. Huth R, Pokorná L. *International Journal of Climatology*. 2005;25(4):469–484.
9. Peticolas WL. *Annual Review of Physical Chemistry*. 1972;23(1):93–116.
10. Kalili KM, de Villiers A. *Journal of Separation Science*. 2011;34(8):854–876.
11. Andrews S, Nover D, Schladow SG. *Limnology and Oceanography: Methods*. 2010;8(10):507–526.
12. Gao Z, Xu F, Zhou C, Zhang H. *Processes*. 2022;10(7):1343.
13. Shanmugam S. *BioImpacts*. 2015;5(1):55–63.
14. Chandramohan LS, Doolla S, Khaparde SA. *International Journal of Emerging Electric Power Systems*. 2016;17(1):49–58.
15. Bhavyasri K, Vishnumurthy KM, Rambabu D, Sumakanth M. *GSC Biological and Pharmaceutical Sciences*. 2019;6(3):089–106.
16. Mercier SM, Diepenbroek B, Wijffels RH, Streefland M. *Trends in Biotechnology*. 2014;32(6):329–336.
17. Londos C, Sztalryd C, Tansey JT, Kimmel AR. *Biochimie*. 2005;87(1):45–49.

Books

1. Dickens JE. Overview of Process Analysis and PAT. In: **Process Analytical Technology: Spectroscopic Tools and Implementation Strategies for the Chemical and Pharmaceutical Industries**. 2010.
2. Sacré PY, De Bleye C, Hubert P, Ziemons E. PAT Applications of NIR Spectroscopy in the Pharmaceutical Industry. In: *Portable Spectroscopy and Spectrometry*. 2021.
3. von Elbe JH, Schwartz SJ. Ultraviolet and Visible Spectrophotometry. In: *Food Analysis*. 2017.
4. Park YW, Bell LN. Determination of Moisture and Ash Contents of Foods. 2004.
5. Abraham J. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. In: *Handbook of Transnational Economic Governance Regimes*. 2010.
6. Gonnet GH, Baeza-Yates RA, Snider T. New Indices for Text: PAT Trees and PAT Arrays. In: *Information Retrieval: Data Structures & Algorithms*. 1992.

C. Thesis / Dissertation

1. Kumar S. Improving Blend Uniformity and Process Monitoring to Achieve Robust Oral Solids Manufacturing Processes. Doctoral Dissertation, Purdue University.

D. Conference / Proceedings

- None as standalone conference papers (Reference 19 is a **book chapter**, not conference proceedings).

E. Patent References

None.

REFERENCES

1. U.S. Food and Drug Administration (FDA). Guidance for Industry: PAT—A Framework for

Innovative Pharmaceutical Development,
Manufacturing, and Quality Assurance.
<https://www.fda.gov>

2. International Council for Harmonisation (ICH).
Official ICH Guidelines (Q, S, E, M Series).
<https://www.ich.org>.

Cite: Akshaya A., Sarumathi B., Roja K.*, Saminathan C., Review on Process Analytical Technology in Pharmaceutical Manufacturing, *Int. J. Med. Pharm. Sci.*, 2026, 2 (8), 465-475. <https://doi.org/10.5281/zenodo.21917909>